Orforglipron
Oral Small-Molecule GLP-1 Receptor Agonist · Weight Loss & Diabetes
First oral non-peptide GLP-1 completing Phase 3 trials. Achieves substantial weight loss without injections, refrigeration, or dietary restrictions, with clinical evidence of 12.4% weight reduction at 72 weeks.
Overview
First oral non-peptide GLP-1 completing Phase 3 trials. Achieves substantial weight loss without injections, refrigeration, or dietary restrictions, with clinical evidence of 12.4% weight reduction at 72 weeks.
Small-molecule GLP-1 receptor agonist with biased signaling preferentially activating G protein/cAMP pathways, enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite while minimizing receptor desensitization. 79.1% oral bioavailability with 29-49 hour half-life.
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
ATTAIN-1 demonstrated 12.4% weight loss (27.3 lbs) at 72 weeks with 36mg dose; 59.6% achieving ≥10% weight loss.
ATTAIN-2 showed 10.5% weight loss with 72.8% achieving ≥5% weight loss.
Improvements in waist circumference, systolic blood pressure (8-12 mmHg), triglycerides (-20-30%).
91% achieved near-normal blood sugar levels versus 42% with placebo.
ACHIEVE-1 Phase 3 trial showed HbA1c reductions of 1.3-1.6% from 8.0% baseline; 76.2% achieving HbA1c <7%.
Significant improvements in insulin sensitivity indices within 4 weeks of therapy initiation.
A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.
- Class
- Small-molecule GLP-1R agonist
- Molecular weight
- 882.974 Da
- Half-life
- ~46.6 h
- Typical dose
- Start 3-6mg daily, titrate up to 12-36mg based on response
- Frequency
- Once daily oral tablet
- Cycle length
- Long-term continuous therapy (72+ weeks in trials)
- Storage
- Room temperature 15-30°C; no refrigeration needed
Molecular data
- Type
- Small-molecule GLP-1R agonist
- Molecular weight
- 882.974 Da
- Half-life
- 2796 min
Dosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| Type 2 diabetes initiation | Oral tablet | 3mg daily | Once daily, any time |
| Type 2 diabetes moderate control | Oral tablet | 12mg daily | Once daily, any time |
| Type 2 diabetes optimal control | Oral tablet | 36mg daily | Once daily, any time |
| Weight loss initiation | Oral tablet | 6mg daily | Once daily, any time |
| Weight loss optimization | Oral tablet | 36mg daily | Once daily, any time |
Interactions
Both are GLP-1 agonists; combining increases severe hypoglycemia and excessive GI adverse effects.
Dual GIP/GLP-1 agonist overlaps with GLP-1 mechanism; combination contraindicated.
Another GLP-1 agonist; concurrent use contraindicated due to overlapping mechanisms.
Orforglipron enhances insulin sensitivity; may require significant insulin dose reduction.
Complementary mechanisms for diabetes management; Phase 3 trials showed enhanced efficacy.
No known interactions; may support gut health and potentially mitigate GI adverse effects.
Quality checklist
- ✓Intact tablet packaging with proper labeling, batch numbers, and expiration dates
- ✓Uniform tablet appearance without discoloration, chipping, or cracking
- ✓Proper storage at room temperature (15-30°C)
- !As of late 2025, orforglipron remains investigational only; any product claiming FDA approval is fraudulent
- ×Discolored, crumbling, or damaged tablets indicate improper storage
- ×Moisture exposure or humidity damage
What to expect
Safety
- Diarrhea (more prevalent than with injectable GLP-1s)
- Nausea (typically improves after first month)
- Appetite reduction
- Severe or persistent abdominal pain radiating to back (potential pancreatitis)
- Neck lumps, hoarseness, difficulty swallowing, or neck swelling
- Severe nausea/vomiting preventing adequate nutrition or hydration
- Signs of severe hypoglycemia (confusion, sweating, rapid heartbeat)
- Suicidal thoughts, severe depression, or significant mood changes
- Vision changes or persistent eye pain
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Pregnancy and breastfeeding
FAQ
How does orforglipron compare to semaglutide for weight loss?
Orforglipron achieved 12.4% weight loss vs semaglutide's 15-20% in trials, but orforglipron is an oral tablet while semaglutide requires weekly injections. For many people, the convenience of taking a daily pill outweighs slightly lower weight loss numbers. It's still in Phase 3 trials (not yet FDA-approved), while semaglutide is established.
Why does orforglipron cause more diarrhea than other GLP-1s?
The file specifically notes that diarrhea is more prevalent with orforglipron than with injectable GLP-1s. This is likely due to its oral bioavailability and how the small molecule formulation affects the GI tract differently than peptide injections. Diarrhea typically improves after the first month as your body adapts.
Can I take orforglipron with food, or does it need an empty stomach?
Orforglipron can be taken with or without food and at any time of day, according to the protocols. This flexibility is a key advantage over some other GLP-1 formulations. You don't need to plan around meals for administration.
Is orforglipron safe if I have a family history of thyroid cancer?
No. Orforglipron is contraindicated if you have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Like other GLP-1 agonists, there's a theoretical risk of thyroid C-cell tumors. Discuss your family history thoroughly with your healthcare provider before starting.